Prosegur Cash Q3 2026 slides: sales accelerate, FCF jumps 10%

Prosegur Cash reported nine-month 2026 sales of €1.51B, up 1.4%, with standalone Q3 growth accelerating to 5.3%; net income rose 2.1% to €68M while EBITA fell 2.4% to €160M and its margin declined to 10.6% from 11.0%. Free cash flow increased 10% to €83M, net debt fell €53M year over year to €784M, and leverage improved to 2.2x from 2.3x. Transformation products reached 36.2% of sales, while Asia-Pacific organic growth was 13.5%; management expects 2026 capex slightly above 2025’s €82M and projects a €90M–€100M range going forward. Shares rose 2.08% to $0.688, and S&P improved its outlook to BBB stable.

Analysis

The key question is whether Q3 acceleration reflects durable underlying demand or a favorable currency/comparison mix. Until standalone organic growth is confirmed, the reported rebound is not enough to underwrite a sustained earnings upgrade. Cash-acceptance rules may protect access to cash, but they do not ensure higher cash usage or outsourced volumes; in low-density markets, mandated acceptance could add service complexity without improving route economics.

The higher-value mix is strategically constructive only if it raises contribution margins and returns on capital. Verify that transformation growth translates into margin improvement rather than merely replacing traditional volumes. Near term, reported earnings also have support from tax and working-capital factors that may not recur. Rising capex could absorb part of the cash-flow benefit, while the reported leverage improvement partly reflects lower lease debt, not just operating deleveraging.

Over 1–3 months, the next results and guidance should distinguish organic momentum from FX and show whether EBITA margins stabilize. Over 6–18 months, Asia-Pacific offers growth optionality, but its small revenue base and adverse currency translation can mute group-level gains; Argentina is a margin-recovery option, not yet a base case. The contrarian risk is treating cash’s regulatory relevance as a growth catalyst: acceptance is not equivalent to transaction share or profitable outsourcing demand.

Key Decisions for Investors

• Consider only a modest, staged long in CASH ahead of the next reporting date; add only if management confirms Q3 organic acceleration and transformation growth is accompanied by stable or improving EBITA margins. Avoid options absent evidence of suitable liquidity.
• Track organic growth by region, FX contribution, transformation-product margins/returns, and working-capital versus tax contributions to free cash flow. These are the missing proof points for an earnings-quality upgrade.
• Treat Argentina recovery and Asia-Pacific scale benefits as upside scenarios rather than valuation anchors. Reassess if regional organic growth slows materially or currency translation continues to erase local growth.
• Falsify the constructive thesis if the next update shows renewed sales deceleration, further EBITA margin compression, or capex growth consuming the cash-flow improvement; do not interpret acceptance mandates alone as evidence of incremental revenue.